Cancer remains one of the most complex challenges. If we have a look at numbers, in 2020, approximately 19.3 million new cancer cases emerged worldwide, claiming nearly 10 million lives [1]. By 2022, that figure had climbed to 20 million new diagnoses annually – one in five people will develop cancer during their lifetime [2]. Perhaps even more striking? Projections suggest 35 million new cases of oncology by 2050, representing a 77% increase in just three decades [2].
These statistics isn't just numbers. Behind it are thousands of people that seek hope when traditional treatments fall short or bring unbearable side effects. Chemotherapy, radiation, and surgery form the basis of cancer care. But their limitations become painfully apparent in advanced disease – particularly when tumors develop resistance or when treatment toxicity becomes as devastating as the disease itself.
Innovative approaches are emerging and electrochemotherapy (ECT) represents one such advancement: a non-surgical cancer treatment that enhances the effectiveness of chemotherapeutic drugs in combination with reducing their toxic burden on patients. With the help of combining precisely delivered electrical pulses and a very low dose of medication ECT opens tumor cell membranes – allowing drugs to penetrate where they're needed most. The result? More effective treatment, fewer side effects, better quality of life.
Non-ablative electrochemotherapy (NA-ECT) is a possibility for patients who've exhausted conventional options or need gentler alternatives. But understanding when and how this treatment works best is essential and that requires looking deeper into its mechanisms, the treated areas, and outcomes.
How Electrochemotherapy ECT Works in Cancer Patients
Let’s think of cell membranes as fortress walls. Chemotherapy drugs must breach that to destroy cancer cells – yet many oncology drugs struggle to penetrate. Traditional chemotherapy compensates for this obstacle by flooding the entire body with toxic medication and hoping enough reaches the tumor… This approach brings two problems: inadequate drug concentrations at the tumor site and severe toxicity throughout normal tissues.
It is electrochemotherapy that changes this equation fundamentally. The procedure combines two elements: administration of chemotherapeutic agents and delivery of short, intense electrical pulses through needle electrodes positioned precisely within or around the tumor [3]. These electric pulses last microseconds – typically eight electric pulses of 100 microseconds each – but their impact is profound. The electrical field temporarily increases cell membrane permeability through a phenomenon called electroporation (EP), creating transient pores that allow drugs to flood into cancer cells [4].
Here's what makes this remarkable: electroporation enhances drug uptake by 80 to 300-1000 for different medications [5]. Suddenly, physicians can achieve superior therapeutic effects using a small part of the drug doses required in conventional chemotherapy. Less medication means dramatically reduced systemic toxicity. The treatment remains localized – only cells within the electrical field gain increased permeability, sparing surrounding healthy tissue.
The mechanism is simple. After drug administration (either administered intravenously or directly into the tumor), electrodes are inserted using image guidance – ultrasound, CT, or direct visualization during surgery. Computer-controlled generators calculate optimal parameters of electric pulses based on electrode positioning and tumor geometry. The electrical pulses open membrane pores for approximately 5 minutes – during which drugs enter cancer cells en masse. When membranes restore naturally, drugs remain trapped inside: and here they disrupt DNA, prevent cell division, and trigger apoptosis.
| Phase | What Happens | Effects of electrochemotherapy |
|---|---|---|
| Before Pulse | Chemotherapy drug surrounds tumor cells in the treated area | Drug present but cannot enter cells |
| During Pulse | High-intensity electrical field applied to tumor | Cell membranes develop temporary pores (tumor cell electroporation) |
| Immediate Post-Pulse | Drugs go through open pores into cells | 80-1,000 x increased intracellular drug concentration |
| Membrane Resealing | Cell membranes close, trapping drugs inside the treated area | Drugs remain concentrated inside tumor cells |
| Therapeutic Effect | Drugs disrupt DNA and fatally damage cancer cells | Tumor cell death |
| Clinical Outcome | Tumor shrinkage, potential complete response | Measurable reduction in tumor size after cancer treatment without surgery |
Indications and Clinical Applications of ECT Treatment
High-rate electrochemotherapy (HR-ECT) demonstrates effectiveness across diverse tumor types, though response rates vary depending on tumor characteristics – particularly blood supply and tissue architecture.
Primary Indications for Electrochemotherapy Treatment (ECTx)
Head and Neck Tumors. The EURECA (European Research on Electrochemotherapy in Head and Neck Cancer) project demonstrated 89% overall disease-free survival after one year – this is for skin and mucosal tumors. For recurrent mucosal cancers, objective response rates reached 56% even when conventional treatments failed [7].
Anal Cancer. Recent clinical studies demonstrate exceptional outcomes for anal squamous cell carcinoma. Let’s have a look at the clinical case study: in a series of 4 patients treated with isolated hypoxic pelvic perfusion combined with electrochemotherapy, all achieved complete clinical and pathological remission – maintaining 100% colostomy-free survival with disease-free periods ranging from 8 to 48 months [8]. This represents an obvious improvement over traditional abdominoperineal resection (which requires permanent colostomy – very inconvenient for a patient) or standard chemotherapy protocols (with severe toxicity). The treatment offers organ preservation without the devastating side effects of conventional radiochemotherapy. And this is what matters for cancer patients.
Breast Cancer. Cutaneous and subcutaneous metastases from breast cancer respond exceptionally well to ECT. Studies show 75-99% objective response rates, with particularly impressive outcomes in elderly or debilitated patients who tolerate standard chemotherapy protocols poorly [9]. The treatment offers relief and local control without compromising quality of life. Primary tumors are also an indication for this treatment.
Pancreatic Cancer. Phase I/II trials in locally advanced pancreatic cancer show ECT is effective and safe, with encouraging early results in local disease control and symptom management. For a cancer type characterized by resistance and poor prognosis, any improvement matters profoundly.
Cervical Cancer. Doctors can treat primary tumors and recurrences with ECT – with research demonstrating growth inhibition in cervical cancer cell lines [10].
Cutaneous and Subcutaneous Metastases. As according to the literature, ECT achieved objective response rates of 85.3% in the landmark ESOPE trial, with complete responses in 56.4% of evaluable tumors of various histologies [6]. The treatment excels in managing basal cell carcinoma and melanoma metastases, with studies showing 100% disease-free survival at 1 year for some patient groups [7].
Other Malignancies. Clinical experience also includes bile duct tumors, gastric cancer, esophageal cancer, osteosarcoma, ovarian cancer, and pleural mesothelioma. Evidence is being collected, and more and more applications are appearing.
Electrochemotherapy in Comprehensive Treatment Strategies
ECT rarely is used alone – the power of this interventional oncology (IO) method amplifies when integrated thoughtfully with other therapies. It is important to find a healthcare practitioner who is keen on all methods so that the scheme will not be limited to the standard options.
ECT + Regional Chemotherapy. Local electrochemotherapy (L-ECT) is combined with regional perfusion techniques – delivering concentrated chemotherapy to specific body regions before applying electrical pulses. This combination achieves very high drug concentrations at tumor sites. Residual chemotherapy may be filtered from the bloodstream that minimizes systemic exposure. For liver metastases, pelvic tumors, and extremity sarcomas, this approach demonstrates superior local control compared to either treatment alone.
ECT + Hyperthermia. When tumors are heated to 38-39°C, this increases blood flow and via this mechanism, enhances drug delivery. Studies combining regional hyperthermia with chemotherapy show improved response rates in melanoma, pancreatic cancer, and liver metastases. When electrochemotherapy follows hyperthermia treatment, the synergistic effect can be great – enhanced perfusion delivers more drugs to the tumor, while electroporation ensures those drugs penetrate cells efficiently. This is a combination of choices for many patients.
ECT + Immunotherapy. As the emerging evidence suggests, electrochemotherapy may trigger immunogenic cell death, potentially making the immune system to recognize and attack cancer cells throughout the body more actively. This is because during the cellular death after ECT multiple tumor antigens enter the bloodstream. Clinical trials that combine ECT with immune checkpoint inhibitors are carried out in melanoma, hepatocellular carcinoma, and squamous cell carcinoma.
Neoadjuvant ECT. Electrochemotherapy before surgery can shrink tumors – making previously inoperable cancers resectable. In breast cancer, this approach makes it possible to carry out breast-conserving surgery instead of a mastectomy. For pancreatic cancer, tumor downsizing may convert borderline resectable cases into surgical candidates.
Other options like electrochemotherapy combined with radiofrequency ablation (ECT-RFA) and electrochemotherapy and photodynamic therapy (ECT-PDT) are also possible.
How an ECT Treatment Session is Carried Out
Treatment typically occurs under local anesthesia for small tumors or general anesthesia for larger treatment areas, with most procedures completed within 30-60 minutes. Patients experience minimal discomfort – some muscle contractions occur during pulse delivery, but pain remains manageable. Many patients walk within hours of treatment.
| Aspect | Details |
|---|---|
| Setting | Outpatient procedure (small tumors) |
| Anesthesia | Local or general, depending on tumor size and location |
| Patient position | Comfortable position allowing electrode access to tumor |
| Monitoring | ECG synchronized (to avoid cardiac vulnerable phase) |
| Muscle contractions | Brief, involuntary during pulse delivery (painless under anesthesia) |
| Immediate post-procedure | Patients mobile within hours |
| Typical sessions needed | 1-2 treatments (evaluated at 3-week intervals) for maximum effects of electrochemotherapy |
| Repeatability | Can be repeated if needed, no cumulative toxicity limit |
| Hospital stay | Usually day procedure; overnight for extensive treatments |
Benefits and Limitations of ECT Cancer Treatment
The benefits of ECT for cancer patients extend beyond response rates. And this is why the method is gaining popularity among care providers and patients.
- Reduced Systemic Toxicity. Using drug in very low dose – 10-20 times lower than conventional chemotherapy – decreases side effects. Patients avoid common chemotherapy complications – severe nausea, hair loss, bone marrow suppression, and peripheral neuropathy become rare rather than expected [11].
- Organ Preservation. For tumors in cosmetically or functionally sensitive treated areas – face, genitals, hands – ECT provides effective local control without tissue destruction.
- Repeatability. Unlike radiation therapy (which has cumulative dose limits) or surgery (with increasing technical difficulty in previously operated fields), electrochemotherapy can be repeated – up to multiple times if needed.
- Cost-Effectiveness. Analysis shows favorable ECT treatment cost-benefit ratios compared to alternatives like isolated limb perfusion or hyperthermia combined with radiotherapy.
- Quality of Life. Patients consistently report preserved or improved quality of life. The ability to walk, eat, and function normally shortly after treatment contrasts sharply with the debilitating effects of intensive systemic chemotherapy.
- Synergistic Potential. When combined with regional chemotherapy, hyperthermia, or immunotherapy, ECT demonstrates synergistic effects – the whole exceeds the sum of its parts. Combined regional hyperthermia and chemotherapy increased therapeutic efficacy compared to chemotherapy alone in cancer metastases.
Important Limitations
No treatment is universally effective. Understanding ECT's limitations helps have realistic expectations.
Tumor Accessibility. Electrochemotherapy works best for tumors reachable by electrodes. While advancing technology enables treatment of deeper tumors (including liver, pancreas, and bone metastases), some anatomical locations remain challenging. And tumors near major blood vessels or vital structures require exceptional care.
Variable Response Based on Histology. Not all cancers respond equally. Poor tumor vascularity correlates with reduced efficacy – drugs must reach cancer cells before electroporation can enhance uptake.
Tumor Size Considerations. Very large tumors may require multiple treatment sessions or combination with other approaches.
Is Electrochemotherapy in Germany Worth Trying?
Electrochemotherapy represents more than one treatment technique – it is a fundamental shift in health and care excellence. Rather than damaging the entire body with toxic drugs hoping enough reaches the tumor, ECT targets treatment precisely where needed, using electrical enhancement to achieve effects with minimal collateral damage.
The evidence base continues growing. From the landmark ESOPE trial demonstrating 85% response rates across multiple tumor types to ongoing investigations in pancreatic cancer and other challenging malignancies, research validates ECT's role in modern oncology. Although it is not a first-line treatment, when combined with regional chemotherapy, hyperthermia, or immunotherapy, outcomes improve further – synergy that offers hope for patients with limited options.
| Method | Systemic toxicity | Severe aesthetic effect | Duration | Cost of treatment |
|---|---|---|---|---|
| Electrochemotherapy | Low, no damage to healthy tissue | Absent | 1-2 treatments – at 3-week intervals | 7,500-12,000€ |
| Standard treatment methods | High (especially systemic chemotherapy) | Significant aesthetic and functional deficit | up to 1 year | Up to €250,000 |
Yet electrochemotherapy isn't a miracle cure or universal solution. Therapy success requires careful patients selection, technical expertise, and often integration with other treatments. Electrochemotherapy may offer what matters most: effective disease control with preserved quality of life. The ability to undergo treatment in the morning and walk hallways by afternoon – to maintain strength, comfort, and dignity while fighting cancer – is invaluable.
As clinical experience with ths therapy is gained, electrochemotherapy's role will likely expand. Cancer treatment should aim not merely to extend life, but to make that life worth living. And electrochemotherapy in the hands of experienced practitioners helps achieve that goal.
A Medical Journey: Every Step of the Way With Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex cancer management programs in each individual case. As a reputable company, Booking Health offers personalized treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you in pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for different types of cancer with leading specialists in this field.
International Cancer Care: Patient Stories with Booking Health
FAQ: Electrochemotherapy for Cancer Treatment
Send request for treatmentTraditional chemotherapy floods the body with high drug doses hoping enough reaches the tumor, causing severe systemic toxicity. Electrochemotherapy uses electroporation – electrical pulses that open cell membranes – allowing 10-20 times lower drug doses to penetrate cancer cells directly, minimizing side effects while maximizing tumor destruction.
ECT cancer treatment achieved 85.3% objective response rates in landmark trials, with complete tumor elimination in 56.4% of cases. For head and neck cancers, 89% disease-free survival after one year was reported. Response varies by tumor type – breast cancer metastases show 75-99% response rates.
Success depends on tumor characteristics, particularly blood supply and location. Localized tumors respond exceptionally well, with some patient groups achieving 100% disease-free survival at one year. Anal cancer patients treated with ECT reached complete remission with 8-48 months disease-free periods.
Unlike radiation therapy with cumulative damage limits, ECT can be safely repeated without long-term toxicity accumulation. Patients avoid chronic chemotherapy complications like peripheral neuropathy or organ damage. The treatment preserves tissue function and cosmetic appearance, maintaining quality of life years after therapy.
The ECT procedure typically takes 30-60 minutes. Electrical pulses last only microseconds – eight pulses of 100 microseconds each. Most patients walk within hours post-treatment. Treatment courses involve 1-2 sessions evaluated at 3-week intervals, with outpatient procedures for smaller tumors.
Electrochemotherapy combines chemotherapeutic drugs with precisely delivered electrical pulses through needle electrodes positioned in tumors. This chemotherapy enhancement technique increases drug uptake by 80 to 1,000-fold, trapping medication inside cancer cells where it disrupts DNA and triggers cell death.
ECT treats head and neck tumors, breast cancer metastases, melanoma, basal cell carcinoma, anal cancer, pancreatic cancer, and cervical cancer. Applications extend to osteosarcoma, ovarian cancer, and pleural mesothelioma, with expanding evidence for advanced cancer cases resistant to conventional therapies.
Most patients experience minimal discomfort during treatment. Small tumors require only local anesthesia; larger areas use general anesthesia. Brief muscle contractions occur during pulse delivery but remain painless under anesthesia. Many patients resume normal activities within hours, contrasting sharply with debilitating conventional chemotherapy effects.
ECT side effects are dramatically reduced compared to conventional chemotherapy. Using very low drug doses, patients rarely experience severe nausea, hair loss, bone marrow suppression, or peripheral neuropathy. Local effects include temporary muscle contractions during treatment, with minimal post-procedure discomfort.
ECT in Germany offers world-leading expertise, particularly at specialized centers like Medias Clinic in Burghausen. Cancer treatment abroad through providers like Booking Health connects patients with experienced practitioners. Medical travel services coordinate everything from clinic selection to follow-up care coordination.
ECT treatment cost varies by tumor size, location, and treatment complexity. Analysis shows favorable cost-benefit ratios compared to alternatives like isolated limb perfusion. Cancer care price through medical travel coordinators often includes transparent budgeting. Contact Germany clinics through Booking Health for personalized cost estimates.
Combined cancer treatment amplifies ECT's effectiveness. It's integrated with regional chemotherapy perfusion, hyperthermia (heating tumors to increase blood flow), immunotherapy, and radiotherapy. Neoadjuvant ECT before surgery can shrink tumors, making inoperable cancers resectable while preserving organs and function.
Eligibility for ECT includes patients with cutaneous or subcutaneous tumors, certain deep-seated cancers, those who've failed conventional therapy, or individuals seeking gentler alternatives. Ideal candidates have accessible tumors with adequate blood supply. Treatment teams assess each case individually based on tumor characteristics and patient health.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660. [DOI]
[2] World Health Organization. Global cancer burden growing, amidst mounting need for services [Internet]. Geneva: WHO; 2024 Feb 1 [cited 2025 Nov 27]. Available from: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services
[3] Miklavčič D, Mali B, Kos B, Heller R, Serša G. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online. 2014;13:29. doi: 10.1186/1475-925X-13-29. [DOI]
[4] Serša G, Miklavčič D, Čemažar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol. 2008;34(2):232-240. doi: 10.1016/j.ejso.2007.05.016. [DOI]
[5] Sadadcharam M, Soden DM, O'Sullivan GC. Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia. 2008;24(3):263-273. doi: 10.1080/02656730701832334. [DOI]
See more
[6] Mir LM, Glass LF, Sersa G, Teissié J, Domenge C, Miklavcic D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols MP, Belehradek J Jr, Bachaud JM, DeConti R, Stabuc B, Cemazar M, Coninx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer. 1998;77(12):2336-2342. doi: 10.1038/bjc.1998.388. [DOI]
[7] Bertino G, Sersa G, De Terlizzi F, Occhini A, Plaschke CC, Groselj A, Langdon C, Grau JJ, McCaul JA, Heuveling D, Cemazar M, Strojan P, de Bree R, Leemans CR, Wessel I, Gehl J, Benazzo M. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur J Cancer. 2016;63:41-52. doi: 10.1016/j.ejca.2016.05.001. [DOI]
[8] Aigner KR, Aigner K, Hendrikx MJH, Bekrentchir A, Aust H. Isolated hypoxic pelvic perfusion combined with electroporation is a valid alternative to traditional therapies for anal squamous cell carcinoma: a case study. Front Oncol. 2025;15:1644317. doi: 10.3389/fonc.2025.1644317. [DOI]
[9] Esmaeili N, Friebe M. Electrochemotherapy: A Review of Current Status, Alternative IGP Approaches, and Future Perspectives. J Healthc Eng. 2019;2019:2784516. doi: 10.1155/2019/2784516. [DOI]
[10] Łapińska Z, Szwedowicz U, Choromańska A, Saczko J. Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment. Molecules. 2022;27(8):2476. doi: 10.3390/molecules27082476. [DOI]
[11] Probst U, Fuhrmann I, Beyer L, Wiggermann P. Electrochemotherapy as a New Modality in Interventional Oncology: A Review. Technol Cancer Res Treat. 2018;17:1533033818785329. doi: 10.1177/1533033818785329 [. [DOI]
[12] Aigner, K.; Selak, E.; Pizon, M.; Aigner, K.R. Arterial Infusion and Isolated Perfusion in Combination with Reversible Electroporation for Locally Relapsed Unresectable Breast Cancer. Cancers 2024, 16, 3991. https://doi.org/10.3390/cancers16233991. [DOI]
Read:
Не знаете, с чего начать?
Свяжитесь с Booking Health
